An Updated Review on the Chemistry, Biological Characteristics and Ana-lytical Techniques of Dapagliflozin

Abstract

Globally, type 2 diabetes mellitus (T2DM) prevalence is increasing. A patient must have lifetime therapy for diabetes to manage it and prevent any complications. There are many different medications that can be used to treat Type 2 diabetes. Still, almost all of them concentrate on the declining insulin sensitivity and secretion that are associated with the onset of the illness. There is growing interest in the development of innovative anti-diabetic medications that are not insulin-reliant because treatments with such insulin-dependent mechanisms of action usually lose their effectiveness over time. One such technique is the inhibition of renal glucose reuptake. Dapagliflozin, the first line of selective sodium-glucose cotransporter 2 inhibitors that re-duce renal glucose reabsorption, is currently being developed as a therapy for Type 2 diabetes. Numerous analytical techniques have been developed for its detection, measurement, and regular quality control procedures. This review deliberates a thorough discussion on the chemistry of Dapagliflozin, all of its pharmacological actions with analytical and bioanalytical analyses, and more information on the clinical trials.